TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05618236
Drug: GROUP S; decurarized with sugammadex.
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Study: NCT05488925
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramal, 50 mg
Study: NCT04775953
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
Study: NCT04775953
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
Study: NCT04775953
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
Study: NCT04775953
Drug: Nafcillin
Normalized name: Nafcillin
DrugBank: Nafcillin (DB00607)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
Study: NCT04775953
Drug: Oxacillin
Normalized name: Oxacillin
DrugBank: Oxacillin (DB00713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
Study: NCT04775953
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
Study: NCT05215925
Drug: HLX07+carboplatin+pemetrexed
Normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HLX07 1500mg q3w+carboplatin+pemetrexed
Study: NCT05215925
Drug: HLX07+docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HLX07 1500mg q3w+docetaxel
Study: NCT05215925
Drug: HLX07
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 1500mg q3w
Study: NCT05127226
Drug: ION582
Normalized name: ION582
DrugBank: ION582 (DB18158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION582 will be administered by IT injection.
Study: NCT05065359
Drug: Rodatristat Ethyl 300 mg BID
Normalized name: Ethyl acetate
DrugBank: Rodatristat (DB18478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, 300 mg, BID 14 days
Study: NCT05065359
Drug: Rodatristat Ethyl 600 mg BID
Normalized name: Ethyl acetate
DrugBank: Rodatristat (DB18478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, 600 mg, BID 14 days
Study: NCT01522092
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg-20mg, tablet, od, 12 months
Study: NCT04738981
Drug: UC-MSC
Normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
Study: NCT04738981
Drug: Anti-CD25 mAb
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
Study: NCT05432934
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
Study: NCT05257798
Drug: IFN-β inhibitor treatment
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
Study: NCT04839016
Drug: SHR-1314
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1314
Study: NCT05217160
Drug: KeraStat® Gel with Morphine application
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.
Study: NCT05732493
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab 300mg, d1, q3w
Study: NCT05732493
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 d1 q3w
Study: NCT05304546
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for IV
Study: NCT05304546
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral QD
Study: NCT05304546
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral BID
Study: NCT04929535
Drug: Hydrogen Peroxide 30 % Topical Solution
Normalized name: hydrogen peroxide 30 % Topical Solution
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
Study: NCT05460455
Drug: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HB0034 and Placebo
Study: NCT00232895
Drug: lipuro propofol
Normalized name: propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00232895
Drug: standard formulation propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05383313
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of psilocybin on treatment-resistant depression
Study: NCT05383313
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect of ketamine on treatment-resistant depression
Study: NCT05383313
Drug: Midazolam Ph. Eur 9.0
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Effect of midazolam on treatment-resistant depression
Study: NCT05237349
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg,sc,d1,Q3W
Study: NCT05237349
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, iv,d1,Q3W
Study: NCT05237349
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m2, op,bid,d1-14,Q3W
Study: NCT05551858
Drug: Proglumide
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (CAS: 6620-60-6.)
Study: NCT05432492
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, specified dose on specified days
Study: NCT05367362
Drug: Minocyclin
Normalized name: Minocyclin
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
Study: NCT06144567
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
Study: NCT05165849
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
Study: NCT06167265
Drug: Cilostazol Tablet 100 mg
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two oral doses (total daily dose of 200 mg)
Study: NCT05392179
Drug: ADX-2191
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
Study: NCT05392179
Drug: ADX-2191
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
Study: NCT05046132
Drug: Setmelanotide
Normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered once daily via SC injection.
Study: NCT05046132
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin capsules via oral administration.
Study: NCT05010096
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05010096
Drug: Elimusertib
Normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04949633
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of labor with oxytocin.
Study: NCT00004878
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004878
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004878
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004878
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04037462
Drug: Dexamthasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
Study: NCT05537272
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
Study: NCT05537272
Drug: Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule
Normalized name: Tamsulosin hydrochloride 400 microgram prolonged-release oral capsule
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
Study: NCT05136508
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
Study: NCT05136508
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
Study: NCT06290596
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemostatic drug.
Study: NCT06290596
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemostatic drug.
Study: NCT05381363
Drug: Inhaled Interferon α2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
Study: NCT05877222
Drug: Daridorexant 10 mg
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
Study: NCT05126004
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Study: NCT04332666
Drug: Angiotensin 1-7
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
Study: NCT04485949
Drug: SOC: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide administered orally.
Study: NCT06458543
Drug: Metronidazole 500 mg
Normalized name: metronidazole 500 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
Study: NCT05877222
Drug: Daridorexant 25 mg
Normalized name: daridorexant 25 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
Study: NCT06500637
Drug: TB006
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
Study: NCT04663750
Drug: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
Study: NCT06436534
Drug: Ganciclovir Oral Capsule
Normalized name: ganciclovir Oral Capsule
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
Study: NCT06436534
Drug: Ganciclovir Simulant Oral Capsule
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
Study: NCT06436534
Drug: Mometasone Nasal
Normalized name: mometasone nasal
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
Study: NCT04871425
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ketamine
Study: NCT04003805
Drug: Nicotine Mini-Lozenge
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
Study: NCT04431388
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using the same AL
Study: NCT04825704
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
Study: NCT04825704
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
Study: NCT00718406
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00718406
Drug: metoprolol plus morphine
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06147570
Drug: HS-10365 capsules
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
Study: NCT04707313
Drug: PF-06882961 (Cohorts 1 and 2)
Normalized name: lidocaine
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
Study: NCT04707313
Drug: PF-06882961 (Cohort 3)
Normalized name: hypromellose
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
Study: NCT06201819
Drug: Liraglutide injection
Normalized name: Liraglutide Injection
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (GLP-1 analog) injection during 3 months
Study: NCT06288932
Drug: Mycophenolate Mofetil (MMF) Treatment
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
Study: NCT06538558
Drug: Tezampanel
Normalized name: Tezampanel
DrugBank: Tezampanel (DB06354)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
Study: NCT05055414
Drug: UI030
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
Study: NCT04891016
Drug: FLOT combined with toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
Study: NCT05975983
Drug: INS018_055
Normalized name: INS018_055
DrugBank: INS018_055 (DB18083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Study: NCT05311319
Drug: HAIC+TQB2450+Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT04913779
Drug: Anti-SARS-CoV-2
Normalized name: Anti-SARS-CoV-2 IgG
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)